Current medical news and unique business news for anyone who cares about the healthcare industry.
PhRMA social media advice? The trade group PhRMA says it’s waiting for guidance from the FDA before offering advice on how drug companies should use social media. That’s not good enough for the Pharma Marketing Blog.
Whatever guidance the FDA may issue, it only will inform the drug industry how to stay within the LETTER of the law (ie, fda regulations). What’s needed, IMHO, is some guidance on BEST PRACTICES that the industry should follow.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
When $5.7B isn’t enough: Cephalon has rejected a $5.7 billion hostile bid from Valeant Pharmaceuticals, arguing that it undervalues the company.
Day of reckoning for the device industry? The medical device industry’s growing political clout, President Obama’s eagerness to show fealty to big business to appear more moderate and a nation desperate for jobs could combine to “create a perfect storm that might lead to one of the biggest safety disasters in the history of medical devices,” says a curiously byline-less article at CurrentMedicine.tv.
“Moribund” biotech IPOs: Venture investors are turning to social networking firms as the biotech IPO market becomes “moribund,” one investment banker says. Another big advantage of social networking companies — no regulatory concerns, so exits happen much more quickly than with biotechs.
We’ve seen this Medicare-cutting movie before: Paul Krugman says the GOP budget plan that takes an axe to Medicare and Medicaid will play out in a familiar fashion in the mainstream, straight-down-the-middle, view-from-nowhere media world.
And we’ll have endless obfuscation, both-sides-have-a-point reporting that misses the key point, which is that the putative savings come entirely from benefit cuts somewhere in the distant future that would, in all likelihood, never actually materialize.
Oh, and the numbers behind the plan don’t make any sense.
What “Revenge of the Nerds” can teach us about pharma: Can modern-day pharma be understood as a parable between nerds (R&D workers) and jocks (CEOs)? Forbes thinks so.
